To visit the old Ventura website, click here.
Ventura Wealth Clients Login here

NSEBSE
NSEBSE
noteThere is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
1D
1W
1M
1Y
3Y
5Y
Max
Open-
High-
Low-
Prev. Close-
Avg. Traded Price-
Volume-

MARKET DEPTH

info2
Total bid0.00
Total ask0.00
OrdersQtyBid
AskQtyOrders

HIGH/LOW

info2
1d
1w
1m
3m
52w

LOW/HIGH

1,151.0511 minutes ago
1,184.0011 minutes ago
arrow

LOWER/UPPER CIRCUITS

956.60
1,434.90
arrow
Jenburkt Pharmaceuticals Ltd Stock performance
arrow

KEY OBSERVATIONS

info
positive
negative
neutral
noteAnnual Revenue,rose 8.03%, in the last year to ₹158.41 Cr. Its sector's average revenue growth for the last fiscal year was 10.8%.
noteAnnual Net Profit,rose 23.42% in the last year to ₹32.06 Cr. Its sector's average net profit growth for the last fiscal year was 38.79%.
notePrice to Earning Ratio,is 16.46, lower than its sector PE ratio of 41.53.
View more

LONG-TERM PRICE ANALYSIS

info
Stock return5Y CAGR : 6.42%
Net profit growth 5Y CAGR : 5.58%
Jenburkt Pharmaceuticals Limited is an India-based company engaged pharmaceutical formulations. The Company is engaged in manufacturing and marketing of speciality and pharmaceutical formulations and healthcare products. The Company manufactures products in two types divsions: consumer divsion and pharmaceutical division. The Company's products under consumer divsion include nocal tablets nocal sachet and nocal granular. The Company's products uner the pharmaceutical division include anti-arthritic anti-osteoporotic antibiotics anti-diabitic neuropathy anti-inflammory analgesics gastro intenstinal dermatologicals aphrodisiac anti-cough cold and allergy anti-ulcerants and anti-malarial. The Company has approximately 50 brands which are promoted through doctors.
personal

Grow your wealth with more research recommendations

+91